The MVP-5 system (Reverse Medical) is indicated to obstruct or reduce the rate of blood flow in the peripheral vasculature, in 3–5mm vessels. The company also announced the first US clinical case along with the US FDA 510k clearance.
“Our first procedure with the MVP-5 was impressive, and consistent with our prior experience with the MVP-3, resulting in accurate and immediate vessel occlusion upon deployment. The device tracked easily through tortuous anatomy, allowing for more precise control than conventional embolization coils. The MVP product line has become an essential device in my lab. I am particularly excited for its utilisation in my growing Interventional Oncology practice,” stated Rahul Patel, assistant professor, Interventional Radiology, Mount Sinai Hospital, New York, USA.
Alex Thomson, vice president Global Sales, Reverse Medical, said: “The MVP-5 system represents an important addition to the MVP product line worldwide, soon to be followed by an MVP-7 and MVP-9, addressing a broad spectrum of peripheral vascular anatomy. Physician enthusiasm from MVP-3 clinical use created strong demand for larger sizes, and we quickly responded. Embolization coils have been known to be the favoured device for vessel occlusion, largely because of no available alternative technology. The MVP has changed this paradigm by consistently demonstrating clinical, safety and economic superiority. The MVP is a platform technology with broad clinical utility for peripheral and eventual additional indications throughout the body.”
